Instil Bio, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 16, 2026, disclosing a net loss of $4.231 million for the third quarter and $13.023 million for the nine months ended September 30, 2026.
Key Highlights
- Q3 2026 net loss: $4.231 million, compared to $13.587 million in Q3 2025, as reported in the filing.
- Nine-month net loss: $13.023 million for the nine months ended September 30, 2026, versus $63.495 million for the same period in 2025.
- Cash and marketable securities: Cash and cash equivalents of $2.544 million and marketable securities of $59.526 million as of September 30, 2026, according to the filing.
- Total assets: $195.645 million as of September 30, 2026, down from $204.515 million as of December 31, 2025.
- Loan payable: $85.057 million outstanding as of September 30, 2026, per the condensed consolidated balance sheet.
- Shares outstanding: 6,781,976 shares of common stock as of November 12, 2026, unchanged from December 31, 2025.
- Accumulated deficit: $740.706 million as of September 30, 2026, compared to $727.683 million as of December 31, 2025.
Instil Bio's Financial Position and Operating Results for the Quarter Ended September 30, 2026
According to the filing, Instil Bio, Inc. (NASDAQ:TIL) reported total operating expenses of $5.985 million for the three months ended September 30, 2026, a decrease from $15.471 million in the same period of 2025. The company's general and administrative expenses were $5.833 million in Q3 2026, compared to $6.344 million in Q3 2025. Research and development expenses declined significantly to $0.233 million in Q3 2026 from $9.127 million in Q3 2025, the filing disclosed.
The filing reported other rental income of $2.697 million and interest expense of $1.554 million for Q3 2026, with interest income of $0.615 million for the same period. For the nine months ended September 30, 2026, the company recorded a gain on contract termination of $1.620 million, as stated in the condensed consolidated statements of operations. Net loss per share on a basic and diluted basis was $(0.62) for Q3 2026 and $(1.92) for the nine-month period, compared to $(2.01) and $(9.58) for the respective prior-year periods.
On the balance sheet, the company reported property, plant and equipment, net, of $111.096 million as of September 30, 2026, a sharp increase from $0.126 million as of December 31, 2025, which the filing attributes in context to reclassification from assets held for sale. Assets held for sale were $112.096 million at December 31, 2025 and zero at September 30, 2026. Total stockholders' equity stood at $102.564 million as of September 30, 2026, down from $112.671 million at December 31, 2025. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company, as indicated on the cover page of the filing.
What Was Disclosed
Instil Bio filed its quarterly report covering the period ended September 30, 2026, disclosing a Q3 net loss of $4.231 million, total assets of $195.645 million, an accumulated deficit of $740.706 million, and 6,781,976 shares outstanding as of November 12, 2026.




Please wait processing your request...